Andrew Orth - Chief Commercial Officer at Krystal Biotech, Inc.

Insider Transactions and Holdings

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Common Stock	100	$13K	$130.00	Jun 9, 2023	Direct
Stock Option (Right to Buy)	37.5K			Jun 9, 2023	Direct	Common Stock

Showing 1 to 2 of 2 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.